Fox Chase patients may be eligible to receive third COVID-19 vaccine dose – Read More
Lori Goldstein, MD, FASCO
About
Professor Emerita, Department of Hematology/Oncology
NCCN, Breast Cancer Panel Member
Specialties
Treatment Focus
- Systemic chemotherapy, hormonal therapy and biologic therapy for early and advanced stage breast cancer
- Clinical and translational trials in breast cancer
Key Awards
Medical Oncology
Treatment Philosophy
Education and Training
Educational Background
- Fellow, Oncology, Division of Cancer Treatment and Division of Cancer Biology and Diagnosis, National Cancer Institute, Washington, DC
- Resident, Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA
- MD, State University of New York Upstate College of Medicine, Syracuse, NY, 1982
Certifications
- American Board of Internal Medicine
- Internal Medicine
- Medical Oncology
Memberships
- National Comprehensive Cancer Network (NCCN)
- Breast Cancer Panel
- Program Director, Breast Cancer Symposium, Fox Chase Cancer Center
- Course Director, Fox Chase Cancer Center Highlights of SABCS CME Program
- American Association for the Advancement of Science
- American Association of Cancer Research
- American Society of Clinical Oncology
- National Accreditation Program for Breast Cancer Centers
- Women in Cancer Research
Honors & Awards
- Philadelphia magazine Top Doctors, 2009-20
- Best Doctors in America® , 2013-15, 2019-2020, Medical Oncology and Hematology
- Forbes Magazine list of 27 Top Breast Cancer Oncologists, 2017
- America’s Top Doctors®, 2012-2017
- Susan G. Komen "Light of Life Award,” 2014
Patient Stories
Karen Lucas
Breast Cancer
Karen Lucas
Breast Cancer
For more than 20 years, I had been diligent about getting annual mammograms, as well as yearly visits to my OB/GYN. At 65 years old, during a routine mammogram in August 2012, my test showed calcification in both my breasts.
Patti Rose
Breast Cancer
Patti Rose
Breast Cancer
At 36, Patti Rose, a wife and mother to seven children, was shocked to learn she had a rare form of breast cancer. Because her husband works in construction and had done several projects for Fox Chase Cancer Center, they knew right away Fox Chase was the right place for Patti's treatment. At Fox Chase, Patti underwent chemotherapy and radiation therapy, followed by a lumpectomy and additional surgery. The experience was extremely difficult, but Patti credits the staff at Fox Chase for giving her a positive outlook and helping her get through it. Today, she is cancer free and could not be more pleased with the treatment she received. "Fox Chase helped me to be positive. If I didn’t have that connection with doctors and nurses and even the security guard that I would talk to every time I was there, I think I would have felt more afraid," she said. "Knowing all those people were praying for me, thinking of me, and trying to get me through it made me feel like I could overcome it."
Laura Marblestone
Breast Cancer
Laura Marblestone
Breast Cancer
Because Laura Marblestone's mother lost her fight with breast cancer at the age of 43, Laura regularly performed breast self-exams. In 1991, she was diagnosed with encapsulated metastatic carcinoma, and a friend recommended she seek treatment at Fox Chase Cancer Center. After a mestectomy and a round of chemotherapy, Laura was considered cancer free, but in 2006, she found a lump in her right breast; the cancer had returned. She underwent a second mastectomy, chemotherapy, and breast reconstructive surgery. "Even though it took me three months to recover, I would do it again in a heartbeat," she said. "The doctors at Fox Chase were thorough--they didn't leave a stone unturned."
Shari Lynn
Breast Cancer
Shari Lynn
Breast Cancer
In 2002, Shari Lynn's husband, Mark, accepted a new job in another state. Together, Shari and Mark made the decision to move their family from New York to Pennsylvania. Shari was like many other moms in her situation. In preparing for the move, she scheduled routine doctor appointments on Long Island so they would not feel pressured to find new physicians right away.
Marlene Haney
Breast Cancer; Colorectal Cancer
Marlene Haney
Breast Cancer; Colorectal Cancer
When Marlene Haney turned 60 in 2013 she decided the best gift she could give herself was a physical she had been putting off. Self–employed and without supplemental health insurance, she says she had not be in a position to see a doctor for over a decade. When her right breast became tender, she realized a trip to the doctor was necessary.
Pages
Research Profile
Research Interests
- Translational studies in breast cancer
- Development of novel therapeutic strategies in breast cancer
- Molecular targeting of breast cancer
Publications
Selected Publications
Blackwell KL, Zaman K, Qin S, Tkaczuk KHR, Campone M, Hunt D, Bryce R, Goldstein LJ, Study G. Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study. Clinical breast cancer, 19(2):97-104.e4, 2019. PubMed
Goldstein, LJ, Gray, R, Badve, S, Childs, BH, Yoshizawa, C, Rosley, S, Shak, S, Baehner, FL, Ravdin PM, Davidson, NE, Sledge, GW, Perez, E, Shulman, LN, Martino, S, Sparano, JA: Prognostic Utility of the 21-Gene Assay in Hormone Receptor Positive Operable Breast Cancer with Classical Prognostic Factors and an Integrator of Classical Clinicopathologic and Treatment Information. JCO, Vol. 26, No. 25, Pg. 4063, September 2, 2008. PubMed
Goldstein, L.J., O’Neill, A., Sparano, J.A., Perez, E.A., Shulman, L.N., Martino, S.,Davidson, N.: Concurrent doxorubicin plus doxetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0-3 positive axillary nodes: results of North American Breast Cancer Intergroup Trial E2197. JCO, Vol. 26, No. 25, Pg. 4092, September 2, 2008. PubMed
Finn, RS, Bengala, C, Strauss, LC, Fairchild, J, Sy, O, Ibrahim, N, Rouche, H, Sparano, J, Goldstein, LJ.: Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study. Clin Cancer Res. 2011 Nov 1;17(21):6905-13.
Tevaarwerk AJ, Gray R, Schneider BP, Smith ML, Wagner LI, Fetting J, Davidson N, Goldstein LJ, Miller KD, Sparano JA. Survival in Metastatic Recurrent Breast Cancer after Adjuvant Chemotherapy: Little Evidence for Improvement Over the Past Three Decades. Cancer. 2013 Mar;119(6):1140-8. PMCID: 3593800
Goldstein, LJ, Tosello-Oliveria, C, Heinrich B, Stemmer SM, Mala C, Kastner S, Bevan P Richters L, Schmalfeldt B, Harbeck N. A Randomized double-blind phase II study of the combination of oral WX-671 plus capecitabine vs capecitabine monotherapy in first-line HER2-negative metastatic breast cancer (MBC). ASCO 2013 Oral presentation, J. Clin Oncol 31, suppl; Abstract 508.
Goldstein LJ, Gurtler J, Del Prete SA, Tjulandin S, Semiglazov VF, Bayever E, Michiels B. Trabectedin as a Single-Agent Treatment of Advanced Breast Cancer After Anthracycline and Taxane Treatment: A Multicenter, Randomized, Phase II Study Comparing 2 Administration Regimens. Clinical Breast Cancer, 14(6):396-404, 2014.
Freedman GM, Fowble BL, Li T, Hwang ES, Schechter N, Devarajan K, Anderson PR, Sigurdson ER, Goldstein LJ, Bleicher RJ.: Risk of Positive Nonsentinel Nodes in Women with 1-2 Positive Sentinel Nodes Related to Age and Molecular Subtype Approximated by Receptor Status. Breast J Vol. 20(4) 358-363, July 2014. PubMed
Adams S, Gray RJ, Demaria S, Goldstein LJ, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, Badve SS.: Prognostic Value of Tumor-Infiltrating Lymphocytes (TILs) in Triple Negative Breast Cancers (TNBC) from two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014 Sept 20; 32(27):2959-67. PMID: 25513417.
Silverman, D, Ruth, KJ, Sigurdson, E, Egleston, BL, Goldstein, LJ, Boraas, M, Bleicher R.: Skin Involvement and Breast Cancer: Are T4b Lesions of All Sizes Created Equal? Journal of the American College of Surgeons. Vol 219(3) 534-544 September 2014. PMCID: 4143438.
Matro J, Walia R, Tumelty K, Morrison T, Goldstein LJ.: Bilateral Hypoglossal Nerve Palsy Due to Breast Cancer Skull Base Metastases. AJHO Vol 10(5) 14-16, Nov. 2014.
Additional Publications
Professor Emerita, Department of Hematology/Oncology
NCCN, Breast Cancer Panel Member
Specialties
Treatment Focus
- Systemic chemotherapy, hormonal therapy and biologic therapy for early and advanced stage breast cancer
- Clinical and translational trials in breast cancer
Key Awards
Medical Oncology
Treatment Philosophy
Education
Educational Background
- Fellow, Oncology, Division of Cancer Treatment and Division of Cancer Biology and Diagnosis, National Cancer Institute, Washington, DC
- Resident, Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA
- MD, State University of New York Upstate College of Medicine, Syracuse, NY, 1982
Certifications
- American Board of Internal Medicine
- Internal Medicine
- Medical Oncology
Memberships
- National Comprehensive Cancer Network (NCCN)
- Breast Cancer Panel
- Program Director, Breast Cancer Symposium, Fox Chase Cancer Center
- Course Director, Fox Chase Cancer Center Highlights of SABCS CME Program
- American Association for the Advancement of Science
- American Association of Cancer Research
- American Society of Clinical Oncology
- National Accreditation Program for Breast Cancer Centers
- Women in Cancer Research
Honors & Awards
- Philadelphia magazine Top Doctors, 2009-20
- Best Doctors in America® , 2013-15, 2019-2020, Medical Oncology and Hematology
- Forbes Magazine list of 27 Top Breast Cancer Oncologists, 2017
- America’s Top Doctors®, 2012-2017
- Susan G. Komen "Light of Life Award,” 2014
Research Profile
Research Interests
- Translational studies in breast cancer
- Development of novel therapeutic strategies in breast cancer
- Molecular targeting of breast cancer
Publications
Selected Publications
Blackwell KL, Zaman K, Qin S, Tkaczuk KHR, Campone M, Hunt D, Bryce R, Goldstein LJ, Study G. Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study. Clinical breast cancer, 19(2):97-104.e4, 2019. PubMed
Goldstein, LJ, Gray, R, Badve, S, Childs, BH, Yoshizawa, C, Rosley, S, Shak, S, Baehner, FL, Ravdin PM, Davidson, NE, Sledge, GW, Perez, E, Shulman, LN, Martino, S, Sparano, JA: Prognostic Utility of the 21-Gene Assay in Hormone Receptor Positive Operable Breast Cancer with Classical Prognostic Factors and an Integrator of Classical Clinicopathologic and Treatment Information. JCO, Vol. 26, No. 25, Pg. 4063, September 2, 2008. PubMed
Goldstein, L.J., O’Neill, A., Sparano, J.A., Perez, E.A., Shulman, L.N., Martino, S.,Davidson, N.: Concurrent doxorubicin plus doxetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0-3 positive axillary nodes: results of North American Breast Cancer Intergroup Trial E2197. JCO, Vol. 26, No. 25, Pg. 4092, September 2, 2008. PubMed
Finn, RS, Bengala, C, Strauss, LC, Fairchild, J, Sy, O, Ibrahim, N, Rouche, H, Sparano, J, Goldstein, LJ.: Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study. Clin Cancer Res. 2011 Nov 1;17(21):6905-13.
Tevaarwerk AJ, Gray R, Schneider BP, Smith ML, Wagner LI, Fetting J, Davidson N, Goldstein LJ, Miller KD, Sparano JA. Survival in Metastatic Recurrent Breast Cancer after Adjuvant Chemotherapy: Little Evidence for Improvement Over the Past Three Decades. Cancer. 2013 Mar;119(6):1140-8. PMCID: 3593800
Goldstein, LJ, Tosello-Oliveria, C, Heinrich B, Stemmer SM, Mala C, Kastner S, Bevan P Richters L, Schmalfeldt B, Harbeck N. A Randomized double-blind phase II study of the combination of oral WX-671 plus capecitabine vs capecitabine monotherapy in first-line HER2-negative metastatic breast cancer (MBC). ASCO 2013 Oral presentation, J. Clin Oncol 31, suppl; Abstract 508.
Goldstein LJ, Gurtler J, Del Prete SA, Tjulandin S, Semiglazov VF, Bayever E, Michiels B. Trabectedin as a Single-Agent Treatment of Advanced Breast Cancer After Anthracycline and Taxane Treatment: A Multicenter, Randomized, Phase II Study Comparing 2 Administration Regimens. Clinical Breast Cancer, 14(6):396-404, 2014.
Freedman GM, Fowble BL, Li T, Hwang ES, Schechter N, Devarajan K, Anderson PR, Sigurdson ER, Goldstein LJ, Bleicher RJ.: Risk of Positive Nonsentinel Nodes in Women with 1-2 Positive Sentinel Nodes Related to Age and Molecular Subtype Approximated by Receptor Status. Breast J Vol. 20(4) 358-363, July 2014. PubMed
Adams S, Gray RJ, Demaria S, Goldstein LJ, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, Badve SS.: Prognostic Value of Tumor-Infiltrating Lymphocytes (TILs) in Triple Negative Breast Cancers (TNBC) from two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014 Sept 20; 32(27):2959-67. PMID: 25513417.
Silverman, D, Ruth, KJ, Sigurdson, E, Egleston, BL, Goldstein, LJ, Boraas, M, Bleicher R.: Skin Involvement and Breast Cancer: Are T4b Lesions of All Sizes Created Equal? Journal of the American College of Surgeons. Vol 219(3) 534-544 September 2014. PMCID: 4143438.
Matro J, Walia R, Tumelty K, Morrison T, Goldstein LJ.: Bilateral Hypoglossal Nerve Palsy Due to Breast Cancer Skull Base Metastases. AJHO Vol 10(5) 14-16, Nov. 2014.
Additional Publications
Related Articles
